Evidence map›Paper›PMID 26098793›Full record

Trial reportPsychological medicine2015

Improved cognitive content endures for 2 years among unstable responders to acute-phase cognitive therapy for recurrent major depressive disorder.

J R Vittengl, L A Clark, M E Thase, R B Jarrett

Open access · greenAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Psychological medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.8field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 1 country.

J R VittenglDepartment of Psychology,Truman State University,Kirksville,MO,USA.
L A ClarkDepartment of Psychology,University of Notre Dame,Notre Dame,IN,USA.
M E ThaseDepartment of Psychiatry,Perelman School of Medicine,University of Pennsylvania,Philadelphia,PA,USA.
R B JarrettDepartment of Psychiatry,The University of Texas Southwestern Medical Center,Dallas,TX,USA.
The University of Texas Southwestern Medical Center · USTruman State University · USUniversity of Notre Dame · USUniversity of Pennsylvania · US

Funding

PROPHYLACTIC COGNITIVE THERAPY FOR DEPRESSIONR01MH058397 · NIMH · UT SOUTHWESTERN MEDICAL CENTER · PI JARRETT, ROBIN B · 2000 to 2011
$4.1M
PROPHYLACTIC COGNITIVE THERAPY FOR DEPRESSIONR01MH058356 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI THASE, MICHAEL E · 2000 to 2010
$3.5M
Are Cognitive Therapy's Antidepressant Effects Durable?R01MH069619 · NIMH · UT SOUTHWESTERN MEDICAL CENTER · PI JARRETT, ROBIN B · 2004 to 2009
$1.7M
Are Cognitive Therapy's Antidepressant Effects Durable?R01MH069618 · NIMH · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI FRIEDMAN, EDWARD S. · 2004 to 2008
$1.5M
Cognitive Therapy for High Risk &Refractory DepressionK24MH001571 · NIMH · UT SOUTHWESTERN MEDICAL CENTER · PI JARRETT, ROBIN B · 2005 to 2009
$625k
NIMH NIH HHS K24 MH001571NIMH NIH HHS K24MH001571NIMH NIH HHS R01 MH058356NIMH NIH HHS R01 MH058397NIMH NIH HHS R01 MH069618NIMH NIH HHS R01 MH069619NIMH NIH HHS R01 MH58356NIMH NIH HHS R01 MH58397NIMH NIH HHS R01 MH69618NIMH NIH HHS R01 MH69619
6 · The paper itself

Abstract

backgroundThe cognitive model of depression suggests that cognitive therapy (CT) improves major depressive disorder (MDD) in part by changing depressive cognitive content (e.g. dysfunctional attitudes, hopelessness). The current analyses clarified: (1) the durability of improvements in cognitive content made by acute-phase CT responders; (2) whether continuation-phase CT (C-CT) or fluoxetine (FLX) further improves cognitive content; and (3) the extent to which cognitive content mediates continuation treatments' effects on depressive symptoms and major depressive relapse/recurrence.

methodOut-patients with recurrent MDD who responded to acute-phase CT (n = 241) were randomized to 8 months of C-CT, FLX or pill placebo (PBO) and followed for an 24 additional months. Cognitive content was assessed approximately every 4 months using five standard patient-report measures.

resultsLarge improvements in cognitive content made during acute-phase CT were maintained for 32 months, with 78-90% of patients scoring in normal ranges, on average. Cognitive content varied little between C-CT, FLX and PBO arms, overall. Small, transient improvements in cognitive content in C-CT or FLX compared with PBO patients did not clearly mediate the treatments' effects on depressive symptoms or on major depressive relapse/recurrence.

conclusionsOutpatients with recurrent MDD who respond to acute-phase CT show durable improvements in cognitive content. C-CT or FLX may not continue to improve patient-reported cognitive content substantively, and thus may treat recurrent MDD by other paths.

Indexed as

Outcome Assessment, Health CareAdultAttitudeCognitive Behavioral TherapyFemaleFluoxetineFollow-Up StudiesHopeHumansMajor Depressive DisorderMaleMiddle AgedRecurrenceSelective Serotonin Reuptake InhibitorsThinkingFluoxetineSelective Serotonin Reuptake InhibitorsCognitive contentcognitive therapycontinuationfluoxetinemajor depressive disorder

Identifiers

PMID26098793
PMCPMC4631666
OpenAlexW2282601687

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.